We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

117 hedge funds and large institutions have $125M invested in Lineage Cell Therapeutics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

122% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 18

15% more funds holding

Funds holding: 102 → 117 (+15)

3.77% more ownership

Funds ownership: 48.64% → 52.41% (+3.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $140M → $125M (-$14.9M)

Holders
117
Holders Change
+15
Holders Change %
+14.71%
% of All Funds
2.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
40
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BC
Broadwood Capital
New York
+$6.72M
2
Axa
Axa
France
+$5.74M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.02M
4
Deutsche Bank
Deutsche Bank
Germany
+$1.53M
5
AG
Artal Group
Luxembourg
+$686K

Top Sellers

1
FM
Family Management
New York
-$374K
2
NFA
Nationwide Fund Advisors
Ohio
-$237K
3
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$164K
4
DWM
Destination Wealth Management
California
-$162K
5
Group One Trading
Group One Trading
Illinois
-$62.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
51
American International Group
New York
$125K +$19K +8,682 +15%
State of Wisconsin Investment Board
52
State of Wisconsin Investment Board
Wisconsin
$123K – – –
CAM
53
ClariVest Asset Management
California
$110K – – –
SFA
54
Sequoia Financial Advisors
Ohio
$105K – – –
California Public Employees Retirement System
55
California Public Employees Retirement System
California
$104K – – –
MC
56
Moors & Cabot
Massachusetts
$99K -$2.2K -1,006 -2%
Russell Investments Group
57
Russell Investments Group
United Kingdom
$92K -$28K -12,801 -21%
Jane Street
58
Jane Street
New York
$84K -$13.9K -6,351 -12%
IP
59
Intellectus Partners
California
$76K – – –
Bank of America
60
Bank of America
North Carolina
$74K +$50.6K +23,159 +140%
CS
61
Credit Suisse
Switzerland
$73K -$57.3K -26,246 -40%
FM
62
Family Management
New York
$70K -$374K -171,233 -82%
VOYA Investment Management
63
VOYA Investment Management
Georgia
$70K – – –
Teacher Retirement System of Texas
64
Teacher Retirement System of Texas
Texas
$70K +$81.5K +37,310 New
Goldman Sachs
65
Goldman Sachs
New York
$64K -$27.1K -12,410 -27%
GC
66
Guggenheim Capital
Illinois
$63K -$12.1K -5,525 -14%
Wolverine Trading
67
Wolverine Trading
Illinois
$61K +$70.8K +32,438 New
BNP Paribas Financial Markets
68
BNP Paribas Financial Markets
France
$58.1K +$49.3K +22,557 +271%
State Board of Administration of Florida Retirement System
69
State Board of Administration of Florida Retirement System
Florida
$49K – – –
Legal & General Group
70
Legal & General Group
United Kingdom
$48K – – –
RIM
71
Regent Investment Management
Kentucky
$48K – – –
Baird Financial Group
72
Baird Financial Group
Wisconsin
$46K – – –
BDS
73
Banco de Sabadell
Florida
$43K +$49.9K +22,860 New
NA
74
NewEdge Advisors
Louisiana
$42K +$38.2K +17,499 New
Simplex Trading
75
Simplex Trading
Illinois
$41K +$48.6K +22,236 New
1 2
3
4 5

LCTX Hedge Fund Activity: Q4 2017 in Review

117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2017, worth a combined $125M — down 11% from $140M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LCTX positions and 7 closed out — a net gain of 16 holders — while 40 added to existing stakes and 18 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $6.72M. The largest seller was Family Management, cutting an estimated $374K.

  • 117 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2017, up from 102 in Q3 2017.
  • Funds reported $125M of Lineage Cell Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 23 funds opened new Lineage Cell Therapeutics positions in Q4 2017 and 7 closed out, a net change of +16 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2017 was Broadwood Capital, an estimated $6.72M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2017 was Family Management, an estimated $374K sold.

Based on aggregated 13F filings for Q4 2017.